Screener
Cullinan Therapeutics, Inc. CGEM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating activities: | ||
| Net loss | $(103,365) | $(118,556) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Equity-based compensation expense | 16,063 | 19,261 |
| Accretion of discount on marketable securities | (1,331) | (4,017) |
| Depreciation and amortization | 158 | 153 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 1,426 | 5,259 |
Item 1. Financial Statements.
FAQ
- What is Cullinan Therapeutics, Inc.'s stock-based comp?
- Cullinan Therapeutics, Inc. (CGEM) reported stock-based comp of $8.45M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Cullinan Therapeutics, Inc.'s stock-based comp decreased by 14.6% year-over-year, from $9.89M to $8.45M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s stock-based comp has grown at a 10.3% compound annual growth rate (CAGR), from $24.38M to $36.04M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Cullinan Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude